ARCHIVES

Cell Therapeutics To Appeal FDA Decision on Pixantrone.

This article is from The Cancer Letter archive.

Vol. 36 No. 33 | September 17, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: Fischinger Hints of “New Player” At FCRF; Gigliotti Named Cancer Control Science Director

December 12, 1986

Research teams link response to Iressa to mutations in EGF receptor.

April 30, 2004

NCCN Launches Outcomes Improvement Program

August 12, 2011

Commission Seeks Comparative Data on Cervical Cancer

August 16, 1991

Maguire Backs Cancer Program But Insists On New Emphasis for Prevention

January 26, 1979

Abraxane and Gemcitabine Improves Overall Survival

November 30, 2012